Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 13,940 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab, Placebo to pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 20
States / cities: Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more

Conditions: Vaping, Nicotine Dependence
Interventions: Double Blind Varenicline, Double Blind Placebo, QuitVaping, This Is Quitting; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 25 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Methamphetamine Use Disorder
Interventions: Pomaglumetad methionil, Placebo, Methamphetamine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Sleep Deprivation, Insufficient Sleep Syndrome, Healthy
Interventions: PowerSleep Stim, PowerSleep Sham; Device
Lead sponsor: Philips Respironics; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 7
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Lehigh Acres, Florida + 4 more

Conditions: Atopic Dermatitis, Atopic Disorders, Eczema, Atopic Eczema
Interventions: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Day to 63 Days
Enrollment: 1,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Durham, North Carolina • Portland, Oregon + 1 more

Conditions: Diabetes Mellitus
Interventions: Alternate site blood glucose testing; Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post-operative Pain, Acute
Interventions: Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pontiac, Michigan

Conditions: Depression, Anxiety, Suicidal Ideation, Eating Disorders
Interventions: Mental Health First Aid; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 2,543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Autism Spectrum Disorder
Interventions: EASE, Supportive Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 21 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Tuscaloosa, Alabama • Pittsburgh, Pennsylvania

Conditions: Lung Transplant
Interventions: Belumosudil, Placebo for Belumosudil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more

Conditions: Healthy Adult Participants
Interventions: TBD09, Placebo; Drug
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Arthritis Knee, Arthritis of Hip
Interventions: Ketorolac Intraarticular Injection, Triamcinolone Intraarticular Injection; Drug
Lead sponsor: Saint Alphonsus Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Graft -Versus-host-disease
Interventions: Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil (MMF), Axatilimab; Procedure · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Memory Disorders
Interventions: Celecoxib; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Hypertension
Interventions: Treprostinil, Standard of Care; Drug · Other
Lead sponsor: Valley Health System; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Paramus, New Jersey

Conditions: Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC), Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Bladder Ca, Bladder Cancer Recurrent, Bladder Cancer Stage IV, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder
Interventions: T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin); Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Macon, Georgia

Conditions: Neurofibromatosis 1, Noonan Syndrome, Legius Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome
Interventions: Waitlist, ACT Intervention; Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obsessive-Compulsive Disorder, OCD
Interventions: Tolcapone, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Meconium Aspiration
Interventions: Lucinactant, Standard Care; Drug · Other
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: Up to 48 Hours
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: Bipolar Depression
Interventions: Lumateperone (ITI-007), Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 42
States / cities: Rogers, Arkansas • Cerritos, California • Costa Mesa, California + 39 more

Conditions: Prostate Cancer
Interventions: Shared decision-making for PSA screening tool; Behavioral
Lead sponsor: Lisa Richarson; Federal
Eligibility: Not listed
Enrollment: 641 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Alcohol Consumption
Interventions: Control, Goal Support (GS), Coaching for Context-specific Peer Support (CCPS); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Fractures, Bone
Interventions: Virtual Reality (VR); Device
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 4 Years to 12 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Search by objective public record fields.

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Varenicline for Nicotine Vaping Cessation in Adolescents

Study of Pomaglumetad and Methamphetamine

A Study of the Effectiveness and Efficacy of the PowerSleep Device

A Community-based Assessment of Skin Care, Allergies, and Eczema

Self Monitoring of Blood Glucose With Finger Tip vs. Alternate Site Sampling: Effect on Long Term Glycemic Control

Adductor Canal Blocks With Bupivacaine and Magnesium After Same-day Discharge Total Knee Arthroplasty Improve Post-operative Pain Relief and Decrease Opioid Consumption: a Prospective Randomized Controlled Trial

Mental Health First Aid for College Students

Emotion Awareness and Skills Enhancement Program

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09

Intraarticular Injections of the Hip and Knee With Triamcinolone Versus Ketorolac: A Randomized Controlled Trial

CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)

BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

Shared Decision Making: Prostate Cancer Screening

Texting to Reduce Alcohol Misuse Pilot Trial

Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis

Virtual Reality During Pediatric Cast Removal